The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and sézary syndrome

Journal of Drugs in Dermatology

Volumn 10, Issue 4, 2011, Pages 403-408

  Sanli, Hatice ^a   Akay, Bengu Nisa ^a   Anadolu, Rana ^a   Ozcan, Muhit ^a   Saral, Secil ^a   Akyol, Aynur ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BEXAROTENE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PENTOSTATIN; PREDNISONE; VINCRISTINE; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ADD ON THERAPY; ADULT; ADVANCED CANCER; ARTICLE; AXILLARY LYMPH NODE; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRACORPOREAL PHOTOPHERESIS; FEMALE; FLOW CYTOMETRY; HUMAN; INGUINAL LYMPH NODE; MALE; MYCOSIS FUNGOIDES; PRURITUS; PUVA; SEZARY SYNDROME; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE COURSE; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PHOTOPHERESIS; SEVERITY OF ILLNESS INDEX; SEZARY SYNDROME; TREATMENT OUTCOME;

EID: 80052903833     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Scheinfeld N. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development. J Drugs Dermatol. 2007;6:757-760.
2. Anadolu RY, Birol A, Sanli H, et al. Mycosis fungoides and Sézary syndrome: Therapeutic approach and outcome in 113 patients. Int J Dermatol. 2005;44:559-565. (Pubitemid 40960117)
3. Chiarion-Sileni V, Bononi A, Fornasa CV, et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer. 2002;95:569-575. (Pubitemid 34810182)
4. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376-388. (Pubitemid 32112849)
5. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol. 2001;19:2456-2471. (Pubitemid 32391217)
6. Duvic M. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: Algorithms. Clin Lymphoma. 2000(suppl 1):51S-55S.
7. Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7:51-58. (Pubitemid 44322770)
8. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood. 2003;101:4267-4272. (Pubitemid 36857787)
9. Sinha AA, Herald P. Advances in the management of cutaneous T cell lymphoma. Dermatol Clin. 1998;16:301-311. (Pubitemid 28205026)
10. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-3115. (Pubitemid 47218059)
11. Kuzel TM, Roenigk HH Jr, Rosen ST. Mycosis fungoides and the Sézary syndrome: A review of pathogenesis, diagnosis, and therapy. J Clin Oncol. 1991;9:1298-1313.
12. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31-39. (Pubitemid 46053039)
13. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007;13:2318-2322. (Pubitemid 46698579)
14. O'Connor OA. Developing new drugs for the treatment of lymphoma. Eur J Haematol Suppl. 2005;66(suppl):150-158. (Pubitemid 40873994)
15. Fantin VR, Richon VM Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res. 2007;13:7237-7242.
16. Martínez-Iglesias O, Ruiz-Llorente L, Sánchez- Martínez R, et al. Histone deacetylase inhibitors: Mechanism of action and therapeutic use in cancer. Clin Transl Oncol. 2008;10:395-398.
17. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351-1356. (Pubitemid 46328465)
18. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol. 2005;125:1045-1052.
19. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21:427-436. (Pubitemid 34123805)
20. Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest. Front Biosci. 2000;5:D479-487.
21. Parmar S, Platanias LC. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol. 2003;15:431-439. (Pubitemid 38147038)
22. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med. 1991;324:933-940.
23. Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Ann NY Acad Sci. 2001;941:123-138. (Pubitemid 32928339)
24. Di Renzo M, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology. 1997;92:99-103. (Pubitemid 27380887)
25. Gardner JM, Introcaso CE, Nasta SD, et al. A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome. J Am Acad Dermatol. 2009;61:112-116.